SYS-CON MEDIA Authors: Gilad Parann-Nissany, Kevin Benedict, Unitiv Blog, Mark R. Hinkle, Glenn Rossman

News Feed Item

Concise Analysis of the International Bolus Injectors Market, 2014 - 2024

DUBLIN, March 5, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/ghwrtz/bolus_injectors) has announced the addition of the "Concise Analysis of the International Bolus Injectors Market, 2014 - 2024" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The injectable drug delivery market holds significant potential for the future. From conventional syringes with vials and painful needles to the modern-day pre-filled syringes, pen-injectors, needle free injectors and auto-injectors, the injectable drug delivery devices market has come a long way.

Taking the concept of self-injectors to a new stratum, Bolus Injectors' have surfaced recently. Also known as non-insulin patch pumps, these devices not only offer a range of benefits to the end users but also provide a number of additional benefits to other stakeholders in the industry.

One of the main drivers for the perceived growth of bolus injectors is the large number of biologics currently under development. A majority of these molecules are highly viscous and are required to be delivered in volumes of greater than 1 ml. The absence of devices which can safely administer these drugs is currently a big unmet need in the market. However, the early signs are encouraging. Despite the uncertainties related to the device development and approval, many companies are investing time, money and resources to develop novel devices.

Key Topics Covered:

1. Executive Summary

2. Introduction

3. Overview And Market Background

4. Target Drugs For Bolus Injectors

5. Product Profiles

6. Market Size And Forecast

7. Swot Analysis

8. Company Profiles

9. Interview Transcripts

10. Conclusion

11. Appendix 1: Tables

12. Appendix 2: List Of Companies

Companies Mentioned:

  • AbbVie
  • Abbott
  • BMS
  • Boehringer Ingelheim
  • Calando Pharmaceuticals
  • Calibra Medical
  • Dekkun
  • Denderon
  • Eisai
  • Elcam Medical
  • Eli Lilly
  • Five Prime Therapeutics
  • Future Injection Technologies
  • Genentech
  • Genethon
  • Isis Pharmaceuticals
  • J&J
  • Janssen Biotech
  • Kyowa Hakko Kirin
  • Lincoln Medical Limited
  • MacroGenics
  • Nuron Biotech
  • Octapharma
  • OncoGenex Technologies
  • Pfizer
  • PhaseBio Pharmaceuticals
  • Roche
  • SteadyMed Therapeutics
  • Synageva BioPharma
  • TaiMed Biologics
  • Takeda Pharmaceuticals
  • VBL Therapeutics
  • West Pharmaceutical Services
  • Xbiotech
  • Ypsomed
  • ZZ Biotech

For more information visit http://www.researchandmarkets.com/research/ghwrtz/bolus_injectors

Media Contact: Laura Wood, +353-1-481-1716, [email protected]

SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.